India to buy 10 million doses of Zydus Cadila's Covid vaccine at Rs. 265 per dose
- IBEF
- November 9, 2021
Drug firm Zydus Cadila stated that it has received an order to supply 10 million doses of its COVID-19 vaccine, ZyCoV-D, to the Indian government at Rs. 265 (US$ 3.5) per dose.
“Zydus Cadila has obtained an order to supply one crore doses of ZyCoV-D, the world's first Plasmid DNA Vaccine, to the Government of India at Rs. 265 (US$ 3.5) per dose and the needle-free applicator being offered at Rs. 93 (US$ 1.2) per dose, excluding GST,” the pharma firm stated in a regulatory filing
The valuation has been settled in consultation with the central government, it stated.
The vaccine will be dispensed using a needle-free applicator set against traditional syringes. The applicator is called ‘PharmaJet’.
The PharmaJet is a needle free applicator to safeguard painless intradermal vaccine delivery which also advances to a substantial decrease in any kind of major side effects.
Zydus Cadila MD Mr. Sharvil Patel said, “We are glad to support the government's vaccination programme with ZyCoV-D. The needle-free application of the vaccination, we hope, will inspire many more to vaccinate and protect themselves from COVID-19, especially children and young adults in the age group of 12 to 18 years.”
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, created indigenously by the company against the COVID-19 virus, Zydus Cadila told.
The vaccine has demonstrated good stability at temperatures of ~25 degrees for at least three months. The thermostability of the vaccine will aid in easy transportation and storage of the vaccine without any problems of fluctuations in temperature, it stated.
ZyCoV-D is the first vaccine approved by India's drug regulator for inoculation of those aged 12 years and above.
The three doses of ZyCoV-D, are to be dispensed 28 days apart. The vaccine was given emergency use authorization (EUA) by the Indian drug regulator on August 20, 2021.
Zydus Cadila has also requested approval for the two dose treatment of the vaccine.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
